Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

NCT04314934 is registered in ClinicalTrials.gov with Anavex Life Sciences Corp. as lead sponsor.

NCT NCT04314934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04314934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
Lead sponsor
Anavex Life Sciences Corp.
Phase
Phase 2/3
Overall status
Completed
Start date
October 10, 2019
Completion date
June 14, 2024
Enrollment
300 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease